Verified Rigor RecordRigor Reviewed

Rigor-Reviewed Manuscript

CTL–doxorubicin (DOX)–gold complex nanoparticles (DOX–AuGCs): from synthesis to enhancement of therapeutic effect on liver cancer model · 10.1039/d0na00758g

Name: Verified Rigor Record — CTL–doxorubicin (DOX)–gold complex nanoparticles (DOX–AuGCs): from synthesis to enhancement of therapeutic effect on liver cancer model · 10.1039/d0na00758g
Item: CTL–doxorubicin (DOX)–gold complex nanoparticles (DOX–AuGCs): from synthesis to enhancement of therapeutic effect on liver cancer model · 10.1039/d0na00758g
Rating: 75
Author: Αlpha¹

Paper source

Read full text

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · July 6, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

WARN

Warnings to address · Interventional Study

Eight dimensions — click a segment for details

Critical

High-priority

Model-reported confidence: moderateReviewer agreement: lowEngine: 7.6.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.
Declared data/code links were not checked for liveness or content.

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper presents a promising nanoparticle system with a clear scientific premise and adequate ethical approvals and biological variable reporting. However, the study design is critically underreported for reproducibility, statistical reporting is imprecise, and no data or code are made available, which are major limitations for a published research article.

Evaluation is based on three independent reviews of the full manuscript text, a copyedit pass, and verification components for citations, statistics, preregistration, and claims. The statistical verification component found no tests with sufficient detail for recomputation, and the preregistration check found no registration. The paper is classified as interventional despite one reviewer's initial observational classification, based on the clear interventional design.

12 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

6 integrity concerns flagged (0 high).

Rigor

Eight Dimensions3 pass · 4 warn · 1 fail

12 major claims1 unsupported5 partial6 supported

The introduction reviews the literature on nanocarriers for cancer therapy, the use of galactose-bearing systems for hepatic targeting, and the properties of gold nanoparticles, citing over 20 references. The rationale for using CTL to target Galectin-1 and the ASGP receptor is clearly explained, leading to the study objectives. Limitations of prior approaches are implicitly addressed through the design of the novel nanocarrier, though not explicitly labeled.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise, citing relevant prior work on gold nanoparticles, targeted drug delivery, and the role of CTL in targeting Galectin-1, with a logical rationale for the study.

Evidence

direct quote[Introduction, paragraph 1-5]

“In this context, nanotechnology-based platforms (as nanocarriers) have emerged as adequate candidates for guiding the drug therapeutic massively and selectively to the tumor”

direct quote[Introduction, paragraph 4]

“CTL (in other papers termed chitlac) is a branched polysaccharide... and to target the Galectin-1 (Gal-1) protein. Gal-1 is in fact considered a novel therapeutic target for cancer”

absence[Introduction, paragraph 5]

Limitations of prior work are not explicitly discussed.

PASSReviewer 2· 85% conf

The paper establishes a clear scientific foundation by citing relevant prior work on gold nanoparticles, CTL targeting, and DOX therapy, and provides a logical rationale for the study.

Evidence

direct quote[Introduction, paragraph 6]

“The role played by CTL is investigated here since it was already shown to stabilize gold clusters in CTL–PEGylated gold nanoparticles, and to target the Galectin-1 (Gal-1) protein.”

direct quote[Introduction, paragraph 5]

“Galactose-bearing vector systems are extensively studied in hepatic targeted therapy as characteristic targeting ligands for the asialoglycoprotein receptors (ASGP-R) expressed on the surface of liver parenchymal cells.”

absence[Introduction]

No explicit discussion of limitations of prior work addressed in this study.

PASSReviewer 3· 90% conf

The paper adequately cites prior work, establishes a rationale for targeting liver cancer with a CTL-coated gold nanocarrier, and addresses limitations of prior approaches.

Evidence

direct quote[Introduction, paragraph 2]

“galactose-bearing vector systems are extensively studied in hepatic targeted therapy as characteristic targeting ligands for the asialoglycoprotein receptors (ASGP-R) expressed on the surface of liver parenchymal cells.”

direct quote[Introduction, paragraph 3]

“The role played by CTL is investigated here since it was already shown to stabilize gold clusters in CTL–PEGylated gold nanoparticles, and to target the Galectin-1 (Gal-1) protein.”

paraphrase[Abstract]

“The paper states that nanotechnology-based platforms can limit side effects and pharmacokinetic problems of standard therapies.”

The paper states animals were 'randomly divided' but does not describe the randomization method or unit. No blinding is mentioned for treatment or assessment. No a priori power analysis is provided. Group sizes are small and unequal (2-5 mice per group), and independent replication is not addressed. The use of controls (saline, CTL alone, DOX in PEG-AuNPs, 5-FU) is adequate for the interventional animal study. Outlier handling and pre-specified inclusion/exclusion criteria are not reported.

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsNOT REPORTED

outlier handlingNOT REPORTED

randomization unitINADEQUATE

inclusion exclusionNOT REPORTED

randomization methodINADEQUATE

replicate distinctionNOT REPORTED

independent replicationNOT REPORTED

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 75% conf

The study design is partially reported but lacks critical details on randomization, blinding, and power analysis, and has issues with group sizes and replication.

Evidence

direct quote[Methods, Animal tests paragraph]

“Animals were randomly divided into five groups”

absence[Methods, Animal tests and throughout]

No mention of blinding.

absence[Methods, Statistical analysis paragraph]

No power analysis reported.

FAILReviewer 2· 90% conf

The study design lacks essential rigor elements: randomization method is not specified, no blinding, no power analysis, no inclusion/exclusion criteria, no outlier handling, and no independent replication. Only controls and randomization unit are adequately reported.

Evidence

direct quote[Methods, Animal tests, paragraph 2]

“Animals were randomly divided into five groups: saline model groups (5 mice), CTL group (2 mice), DOX in PEG–AuNPs (4 mice), DOX–AuGCs (5 mice), and the positive control (5-FU).”

absence[Methods]

Blinding was not mentioned in any part of the methods.

direct quote[Methods, Animal tests, paragraph 2]

“Animals were randomly divided into five groups: saline model groups (5 mice), CTL group (2 mice), DOX in PEG–AuNPs (4 mice), DOX–AuGCs (5 mice), and the positive control (5-FU).”

WARNReviewer 3· 75% conf

The study lacks a power analysis and does not clearly distinguish biological vs technical replicates; randomization is mentioned but the method is not described; blinding is not reported.

Evidence

direct quote[Methods, Animal tests]

“Animals were randomly divided into five groups: saline model groups (5 mice), CTL group (2 mice), DOX in PEG–AuNPs (4 mice), DOX–AuGCs (5 mice), and the positive control (5-FU).”

absence[Methods, Animal tests and Statistical analysis]

No blinding statement is provided

absence[Methods, Animal tests]

No sample size or power calculation is reported

The paper reports that male nude mice (BALB/cA, SPF grade, age 5 weeks) were used. Housing conditions (12:12 h light/dark, 23±3°C, 40-70% humidity, ad libitum food/water) are described. Health status is noted (quarantine, general observation). Species/strain/source are provided with license numbers. Since only males were used, sex justification is not provided, but given the single-sex design, this is a minor gap (though cost/convenience is not the stated rationale). Demographics are not applicable.

Sub-criteria

demographicsN/A

sex reportedADEQUATE

sex justifiedINADEQUATE

age weight healthADEQUATE

housing conditionsADEQUATE

species strain sourceADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are adequately reported for the animal study, including sex, strain, age, weight, housing conditions, and health status.

Evidence

direct quote[Methods, Animal tests paragraph]

“male nude mice (strain: BALB/cA-Grade: SPF; age 5 weeks; Animal production license number SCXK (Yue) 2018-0002, Guangdong Medical Laboratory Animal Center”

direct quote[Methods, Animal tests paragraph]

“housed under 12:12 h light/dark conditions in a temperature controlled environment (23 ± 3 °C). The humidity was controlled at 40-70%.”

absence[Methods, Animal tests paragraph]

No justification for using only male mice.

PASSReviewer 2· 85% conf

Biological variables are adequately reported, including sex, age, strain, source, and housing conditions, but the use of only male mice is not justified.

Evidence

direct quote[Methods, Animal tests, paragraph 1]

“In vivo tests were performed using male nude mice (strain: BALB/cA-Grade: SPF; age 5 weeks; Animal production license number SCXK (Yue) 2018-0002, Guangdong Medical Laboratory Animal Center; ...)”

direct quote[Methods, Animal tests, paragraph 1]

“The nude mice had free access to food and water throughout the experiment, and were housed under 12:12 h light/dark conditions in a temperature controlled environment (23 ± 3 °C). The humidity was controlled at 40–70%.”

absence[Methods]

No justification for using only male mice.

WARNReviewer 3· 90% conf

Sex, age, strain, source, and housing conditions are reported, but sex is not justified (only males used) and health status beyond age/strain is not detailed.

Evidence

direct quote[Methods, Animal tests]

“male nude mice (strain: BALB/cA-Grade: SPF; age 5 weeks; Animal production license number SCXK (Yue) 2018-0002, Guangdong Medical Laboratory Animal Center”

direct quote[Methods, Animal tests]

absence[Methods, Animal tests]

No justification for using only male mice

The paper states that experimental procedures were approved by the Experimental Animal Ethics Committee of Guangzhou University of Chinese Medicine and conducted in accordance with the NIH. An animal use license number is provided (SYXK (Yue) 2018-0001). This meets the criteria for IACUC statement and regulatory compliance. For an animal study, IRB/consent are not applicable.

Sub-criteria

iacuc statementADEQUATE

informed consentN/A

irb ethics statementN/A

regulatory complianceADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are adequately reported, including a named animal ethics committee and compliance with NIH guidelines.

Evidence

direct quote[Methods, Animal tests paragraph]

“Experimental procedures were conducted in accordance with the NIH, and were approved by the Experimental Animal Ethics Committee of Guangzhou University of Chinese Medicine.”

direct quote[Methods, Animal tests paragraph]

“Animal Use License number SYXK (Yue) 2018-0001, Laboratory Animal Center, Guangzhou University of Chinese Medicine”

PASSReviewer 2· 95% conf

Ethical approvals are properly reported, including a named animal ethics committee and compliance with NIH guidelines.

Evidence

direct quote[Methods, Animal tests, paragraph 1]

“Experimental procedures were conducted in accordance with the NIH, and were approved by the Experimental Animal Ethics Committee of Guangzhou University of Chinese Medicine.”

PASSReviewer 3· 90% conf

The study was approved by the Experimental Animal Ethics Committee of Guangzhou University of Chinese Medicine, and compliance with NIH guidelines is stated.

Evidence

direct quote[Methods, Animal tests]

“Experimental procedures were conducted in accordance with the NIH, and were approved by the Experimental Animal Ethics Committee of Guangzhou University of Chinese Medicine.”

direct quote[Methods, Animal tests]

“Experimental procedures were conducted in accordance with the NIH”

The paper identifies organisms (nude mice) with strain, source, and license numbers, which is adequate. Cell lines (HepG2) are mentioned but not authenticated (no source or RRID). No mycoplasma testing is reported. Key reagents like HAuCl4, DOX, PEG, and CTL are identified with vendors, but CTL is from a company (BiopoLife) without a catalog number. Software (GraphPad Prism 5.0, SPSS 13.0) is named but without versions for SPSS. The Agilent Chem Station software version is not given.

Sub-criteria

mycoplasma testingNOT REPORTED

reagents identifiedINADEQUATE

organisms identifiedADEQUATE

antibodies identifiedN/A

cell line authenticationINADEQUATE

software tools identifiedINADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 70% conf

Key resources are partially identified: organisms are well-described, but antibodies, cell lines, mycoplasma testing, and full identification of some reagents and software are missing or inadequate.

Evidence

direct quote[Methods, Animal tests paragraph]

“male nude mice (strain: BALB/cA-Grade: SPF; age 5 weeks; Animal production license number SCXK (Yue) 2018-0002, Guangdong Medical Laboratory Animal Center”

paraphrase[Results, In vivo antitumor efficacy paragraph]

“HepG2 cells were hypodermically injected to generate subcutaneous liver cancer, but no authentication method or source is given.”

direct quote[Methods, Statistical analysis paragraph; Figure 3 legend]

“Statistical analysis of the experimental data was performed by Graph Pad Prism 5.0 software.”

PASSReviewer 2· 70% conf

Key resources are partially identified: mice strain, reagents, and software are adequately reported, but cell line authentication and mycoplasma testing for HepG2 cells are missing, and antibody identification is not applicable.

Evidence

paraphrase[Methods, Animal tests, paragraph 1 and Results, paragraph 1]

“The paper mentions 'human HepG2 cells were hypodermically injected' but does not provide source, authentication, or mycoplasma testing.”

direct quote[Methods, Animal tests, paragraph 1]

“strain: BALB/cA-Grade: SPF; age 5 weeks; Animal production license number SCXK (Yue) 2018-0002, Guangdong Medical Laboratory Animal Center”

direct quote[Methods, Materials and methods, paragraph 1]

“Tetrachloroauric acid (HAuCl 4 ), sodium borohydride (NaBH 4 ), dicarboxylic polyethylene glycol (PEG)-600 (PEG), sodium chloride NaCl (0.9%), phosphate-buffered saline (PBS), EDTA, doxorubicin hydrochloride (DOX), 5-fluoro uracile (5-FU), isoflurane, and paraformaldehyde were purchased from Sigma Aldrich at maximum purity grade.”

WARNReviewer 3· 70% conf

Most reagents and software are identified, but several key resources lack adequate identification (e.g., CTL polymer source, some reagents lack catalog numbers); cell lines and antibodies are not relevant here.

Evidence

direct quote[Methods, Materials and methods]

“Hydrochloride CTL was kindly provided by BiopoLife S.r.l. (Trieste, Italy).”

direct quote[Methods, Animal tests, Table: Experimental conditions]

“5-FU 2.5 mg kg⁻¹”

direct quote[Methods, Statistical analysis]

“Statistical analysis of the experimental data was performed by Graph Pad Prism 5.0 software.”

The paper states the use of one-way ANOVA with Tukey post-hoc test and identifies GraphPad Prism 5.0. However, no verification of ANOVA assumptions (normality, equal variance) is reported. P-values are reported only as thresholds (e.g., p < 0.05) rather than exact values. Effect sizes and confidence intervals are not provided. Data are presented as bar graphs with error bars (SEM) but individual data points are not shown. 2 of 6 applicable criteria are adequate, resulting in a warn.

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciNOT REPORTED

data presentationINADEQUATE

software identifiedADEQUATE

assumptions verifiedNOT REPORTED

mathematical plausibilityN/A

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 65% conf

The statistical analysis is partially adequate: tests are named, but assumptions are not verified, exact p-values are mostly not reported (only thresholds), and effect sizes/confidence intervals are missing. Data presentation shows individual data in figures but error bars are defined as SEM.

Evidence

direct quote[Methods, Statistical analysis paragraph]

“One-way ANOVA and Tukey test methods were used for comparison between groups.”

direct quote[Figure 2 legend and throughout results]

“* p < 0.05 vs. model.”

absence[Methods, Statistical analysis paragraph]

No verification of test assumptions.

WARNReviewer 2· 80% conf

Statistical methods are named (ANOVA and Tukey test) and software is identified, but assumptions are not verified, exact p-values are not reported, effect sizes and confidence intervals are absent, and data presentation lacks individual data points.

Evidence

direct quote[Methods, Statistical analysis, paragraph 1]

“Statistical analysis of the experimental data was performed by Graph Pad Prism 5.0 software. The data were expressed by mean ± SEM. One-way ANOVA and Tukey test methods were used for comparison between groups. Results were considered statistically significant when p < 0.05.”

paraphrase[Results, Figure 2 and Figure 3]

“P-values are indicated by asterisks (* p < 0.05, ** p < 0.01, *** p < 0.001) without exact numerical values.”

paraphrase[Results, Figures]

“Data are presented as bar graphs with error bars (mean ± SEM). No individual data points are shown.”

WARNReviewer 3· 60% conf

Tests are named (ANOVA + Tukey), exact p-values are not reported (only p < 0.05), effect sizes and confidence intervals are absent, and data presentation uses bar graphs with sparse individual points.

Evidence

direct quote[Methods, Statistical analysis]

“Results were considered statistically significant when p < 0.05.”

absence[Methods, Statistical analysis]

Assumptions not verified

direct quote[Results, In vivo antitumor efficacy]

“Data are shown as the mean ± S.E.M.”

The paper does not contain a data availability statement, nor does it deposit raw data in a public repository. No custom code was used, so code sharing is not applicable. However, the absence of a data availability statement for the primary data is a critical gap.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementNOT REPORTED

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 85% conf

No data availability statement, repository deposit, accession numbers, or code sharing are provided, which is a significant omission for a computational/wet lab study.

Evidence

absence[Entire paper]

No data availability statement found.

absence[Entire paper]

No repository accession numbers provided.

FAILReviewer 2· 90% conf

No data availability statement is provided, and the paper does not include any repository deposit or code sharing, which is a significant omission for a study generating original data.

Evidence

absence[Entire manuscript]

No data availability statement found.

WARNReviewer 3· 80% conf

No data availability statement, repository deposit, or code sharing is provided; only a brief mention that supplementary material is available, but it is not linked.

Evidence

absence[Entire paper]

No data availability statement

absence[Entire paper]

No repository or accession numbers

absence[Entire paper]

No code sharing statement

Methods are reasonably detailed for synthesis, characterization, and animal experiments, though some steps refer to previous work. No clinical trial registration is applicable (animal study). Reporting guidelines (e.g., ARRIVE) are not mentioned. All outcomes reported appear to be covered, though pre-specification is not stated. Limitations are briefly discussed (e.g., cardiotoxicity hypothesis). Conclusions are largely proportional to the data, though some statements about 'higher stimulation of immune system' may be slightly overreaching. Funding sources and conflict of interest (none declared) are provided.

Sub-criteria

funding coiADEQUATE

trial registrationN/A

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedINADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 70% conf

Reporting is partially adequate: methods are detailed, limitations are discussed, conclusions are mostly proportional, and funding/COI are stated. However, no trial registration or reporting guideline is provided, and not all outcomes are explicitly linked to pre-specified hypotheses.

Evidence

absence[Entire paper]

No reporting guideline mentioned.

direct quote[Results, DOX-AuGCs cardiotoxicity hypothesis paragraph]

“it cannot be excluded that the molecular recognition between the hepatic asialoglyprotein receptors and galactose-pending groups on CTL may also contribute to the targeting and internalization process”

direct quote[End of paper]

“This work was supported by the National Natural Science Foundation of China [81430063], and Guangdong Provincial Science and Technology Program [2019B030301009]. Conflicts of interest There are no conflicts of interest.”

PASSReviewer 2· 85% conf

Reporting is largely transparent with detailed methods, all outcomes reported, and funding/COI disclosed, but the paper lacks a reporting guideline statement and a limitations discussion.

Evidence

paraphrase[Methods, entire section]

“The methods section includes synthesis protocols, characterization techniques, animal handling, and statistical analysis in sufficient detail.”

absence[Discussion/Conclusions]

Limitations are not discussed.

direct quote[Conclusions and Footnotes]

WARNReviewer 3· 70% conf

Methods are detailed enough for partial replication; limitations are discussed, but the trial is not registered, no reporting guideline is referenced, and some outcomes (e.g., cytokine data) are not fully reported.

Evidence

absence[Methods]

No reporting guideline referenced

direct quote[Results and Discussion, Cardiotoxicity hypothesis]

“To evaluate the chronic myocardial toxicity of DOX, a group of mice were also treated with free DOX. The observation time was extended to 8 weeks after the last administration.”

direct quote[Conflicts of interest]

“Conflicts of interest There are no conflicts of interest.”

19 copyedit issues flagged: mostly clarity, grammar, consistency.

Checked 50 references: 48 verified — 1 retracted, 1 not checked.

Αlpha¹ Rigor Action ItemsFinal pass before journal submission

A published paper with significant methodological and reporting gaps. Informed readers should weigh the lack of randomization details, blinding, power analysis, and data availability as critical threats to validity and reproducibility. A correction or independent re-analysis is warranted to address the unsupported photothermal therapy claim and the retracted citation.

1.
HIGHdata code
Add a data availability statement to the manuscript that explicitly states where raw data (tumor volumes, cytokine levels, ICP-MS results, etc.) are deposited, including a permanent identifier (DOI) from a public repository such as Figshare, Zenodo, or Dryad.
Without this, readers cannot verify or reuse the data — a critical reproducibility gap that may warrant an erratum.
2.
HIGHrigor
Either provide experimental evidence for the claim that 'the nanovector can be used for simultaneous cancer treatment combining chemotherapy with photothermal therapy' or remove the claim, as no data in the paper support photothermal therapy.
An unsupported headline claim can mislead readers and is a scientific integrity concern.
3.
HIGHreporting
Remove or replace the retracted reference (DOI 10.1016/j.jcis.2017.10.055, 'Polyphosphonate ligands: from synthesis to design of hybrid PEGylated nanoparticles toward phototherapy studies') with a valid source.
Citing a retracted paper undermines the evidence base and may indicate a literature review gap.
4.
HIGHrigor
Describe the randomization method (e.g., computer-generated random numbers) and the unit of randomization (individual animal or cage) in the Methods.
Current 'randomly divided' is insufficient for reproducibility; without this, selection bias cannot be assessed.
5.
HIGHrigor
Report blinding procedures: specify whether investigators, caregivers, or outcome assessors were blinded, and if not, justify why.
Unblinded animal studies are at high risk of bias; a correction should address this.
6.
HIGHrigor
Provide an a priori sample size justification or power analysis, or acknowledge the study as exploratory with a note about the small and unequal group sizes (2-5 mice/group).
The CTL group size of 2 mice is inadequate for statistical inference; readers need context to interpret findings.
7.
HIGHstatistics
Report exact p-values (e.g., p = 0.023) instead of only thresholds (p < 0.05), and include effect sizes with confidence intervals for key comparisons.
Threshold-only p-values obscure the precision of evidence; effect sizes are needed for clinical or biological interpretation.
8.
HIGHstatistics
Verify and report ANOVA assumptions (normality, homogeneity of variance) or use robust/non-parametric tests; state the method used.
Without this, the choice of parametric test may be invalid, affecting all reported significance.
9.
MEDIUMreporting
Reference the ARRIVE guidelines for animal studies and include a completed checklist as supplementary material.
Improves reporting completeness and aligns with journal standards for preclinical research.
10.
MEDIUMrigor
Provide authentication details for the HepG2 cell line (e.g., STR profiling, source) and state mycoplasma testing status.
Uncharacterized cell lines can lead to invalid results; this is essential for reproducibility.
11.
MEDIUMrigor
Pre-specify inclusion/exclusion criteria for animals (e.g., tumor size limits, health status) and define how outliers were handled.
Without these, the paper does not demonstrate that results are robust to analytical choices.
12.
MEDIUMother
Provide a scientific justification for the exclusive use of male mice, noting potential sex-specific effects.
Single-sex designs require justification, especially when biological variables are otherwise well reported.
13.
MEDIUMcopyedit
Correct the typo in the title ('pmc 1 CTL–doxorubicin...' → 'CTL–doxorubicin...') and ensure consistent capitalization of group names throughout the manuscript.
Title errors and inconsistent terminology can confuse readers and appear unprofessional.
14.
LOWcopyedit
Replace 'performes greatly attractive overtures' with clearer phrasing (e.g., 'has attracted great attention') in the Introduction.
Grammatical errors and awkward phrasing reduce readability.
15.
LOWcopyedit
Correct 'synthetized' to 'synthesized' in the Methods section.
Standard spelling improves professionalism.

Full text (48,943 chars)Analyzed: Jul 6, 2026

Αlpha¹ assesses methodological rigor, not the importance of the findings. See how we calibrate →